Pharmacist Digest

STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds

STAT

NOVEMBER 15, 2023

Food and Drug Administration were more frequently invalidated due to information misrepresented or withheld from patent examiners than any other industry sector, according to a new analysis. As a result, 75 patents filed by companies in various industry sectors were subsequently invalidated, according to the analysis in JAMA.

What can pharma marketing learn from other regulated industries?

pharmaphorum

AUGUST 17, 2020

The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. Nevertheless, the advent of COVID-19 is forcing pharma, and many other sectors, to make some radical changes. Virtual connections.

Communication

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies

STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum

STAT

AUGUST 31, 2023

The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

Hospitals

Hospitals Nursing Homes Pharmaceutical Companies Pharmaceutical Companies

STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders

STAT

JUNE 7, 2023

BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. ” Califf has an apparent habit of walking into industry meetings and saying precisely what that industry doesn’t want to hear.

Drug Pricing

Drug Pricing Drug Development

STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China

STAT

MARCH 13, 2024

WASHINGTON — The Biotechnology Innovation Organization, an industry trade group, is cutting ties with Chinese company WuXi in response to increasing U.S. government scrutiny of it and other Chinese companies, according to a BIO press release shared with STAT on Wednesday.

Red Jacket: Ken Getz, a champion of clinical trials

PharmaVoice

OCTOBER 27, 2023

Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.

A STAT analysis shows how top drug companies are starting to take action on climate

STAT

SEPTEMBER 28, 2023

But the pharmaceutical industry has lagged behind others when it comes to understanding and cutting down on its climate impact. ” D rug companies are major contributors to climate change, both through direct greenhouse gas emissions and especially through their supply chains. Read the rest…

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

OCTOBER 25, 2023

Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study.

Chemotherapy

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies

Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

PharmaVoice

SEPTEMBER 28, 2023

A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.

Packaging

STAT+: UnitedHealth cyberattack cripples pharmacies’ and hospitals’ ability to process insurance claims

STAT

FEBRUARY 23, 2024

Hospitals, pharmacies, and other health care providers are getting stuck in an insurance processing logjam after UnitedHealth Group disclosed a cyberattack within a recently acquired subsidiary that serves as a central hub for payments across the industry. The company took down its Change Healthcare payment systems, which remain out.

Hospitals

FTC sues private equity firm Welsh Carson, U.S. Anesthesia Partners for allegedly creating a monopoly

STAT

SEPTEMBER 21, 2023

But this lawsuit is novel by also going after a private equity sponsor that it believes hatched the entire alleged scheme — and could serve as a warning to other private equity deals, which have flooded the health care industry. Read the rest…

Hospitals

Cannabis industry scales back its lobbying in Washington

STAT

AUGUST 1, 2023

WASHINGTON – The cannabis industry is dramatically scaling back its presence in Washington. Others like Columbia Care and Pax Labs got rid of their entire lobbying teams. Curaleaf, one the largest cannabis companies in the world, spent nearly 40% less on lobbying in the first half of 2023 than it did at its peak in 2019.

Opinion: STAT+: Continuous manufacturing can help pharma companies save time, money, and more

STAT

JANUARY 6, 2023

The pharmaceutical industry has been slow to adopt a business practice that is faster, safer, and more efficient than its current way of operating; that the FDA has been encouraging the industry to implement more widely for years; and that has been used effectively in other industries for decades.

Drug Development

A biotech tackles drug discovery with transcription factor know-how

PharmaVoice

NOVEMBER 15, 2023

Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

STAT+: FTC says pharmacy benefit managers are stonewalling requests for information

STAT

FEBRUARY 27, 2024

antitrust regulators into pharmaceutical industry middlemen has been stymied because the companies have failed to provide many of the documents that, in some cases, were requested as far back as June 2022. A much-anticipated inquiry by U.S.

Pharmaceutical Manufacturing

Pharmaceutical Manufacturing Documentation

Opinion: Where do we go from here on digital therapeutics?

STAT

FEBRUARY 1, 2024

Though industry voices point to regulatory hurdles as the culprit, deeper structural challenges threaten the future of “software as a medical device” and other digital health technologies, as categorized by the Food and Drug Administration. Read the rest…

Opinion: Americans are obsessed with health and fitness tracking. It’s time for a data diet

STAT

JANUARY 8, 2024

Turn on your TV or open a web browser this January, and you’ll be bombarded with ads for fitness trackers, smart scales, health apps, and other digital innovations promising to streamline your journey to a happier and healthier you. The marketing campaigns work: Each January, fitness app downloads spike 36% higher than usual.

STAT+: U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments

STAT

MAY 25, 2023

government on Thursday unveiled an $800 million package to bolster the life sciences, highlighting officials’ efforts to grow the industry even as biopharma companies have raised alarms about policies they say are deterring them from investing further in the country. has fallen behind other countries in running such studies.

Packaging

Packaging Pharmaceutical Manufacturing

What’s on tap at HLTH, the health care industry jamboree that kicks off this weekend

STAT

OCTOBER 5, 2023

Health leaders are jetting to Las Vegas this weekend for a meeting they say is crucial for clinching new deals and cooking up new startups — all while mingling with TV personalities, social media influencers, musicians and ten thousand other health care professionals on the industry’s flashiest exhibitor floor.

STAT+: Morgan Health wants you to know it’s still here

STAT

JANUARY 9, 2024

SAN FRANCISCO — Almost three years ago, the country’s biggest bank unveiled a lofty plan to fix the health care industry’s entrenched problems. For the uninitiated, it’s usually the other way around. It broke off $250 million to stand up a new business unit, Morgan Health, to do so.

STAT+: Hospitals try a new pitch to investors: other ways of making money

STAT

JANUARY 8, 2024

Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care.

Hospitals

STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more

STAT

MARCH 14, 2024

… The Biotechnology Innovation Organization, the industry trade group, is cutting ties with China’s WuXi in response to increasing U.S. government scrutiny of the biotech and other Chinese companies , STAT tells us. Industry argues innovation will be harmed.

Biosimilars

STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more

STAT

MAY 13, 2024

Known as the Orange Book, it holds a key, behind-the-scenes role in shaping the competitive landscape of the pharmaceutical industry. But The pharmaceutical industry has haggled over the proposed formula. Continue to STAT+ to read the full story…

Diabetes

STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues

STAT

DECEMBER 6, 2023

In a victory for the pharmaceutical industry, a U.S. The order was issued in response to a lawsuit filed last July by the Association for Accessible Medicine, which argued the law gives Minnesota the power to regulate interstate commerce and apply the law to prices charged in other states.

Drug Pricing

Drug Pricing Pharmaceutical Manufacturing

STAT+: Net prices for medicines fell considerably in 2023’s last quarter, mostly thanks to Humira biosimilars

STAT

APRIL 1, 2024

in last year’s fourth quarter, the largest decline ever measured by SSR Health, a research firm that tracks the pharmaceutical industry and its pricing trends. The net prices that health plans paid for medicines — after subtracting rebates, discounts, and fees — fell by 2.8%

Biosimilars

Submit your essay to First Opinion

STAT

AUGUST 16, 2023

First Opinion , STAT’s platform for opinion and perspective essays, welcomes submissions about the biopharma industry, medical science and health care, and other topics related to the life sciences writ large. Here are general guidelines for submissions: Read the rest…

STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing

STAT

JULY 18, 2023

trade group for misleading promotional efforts for its biggest-selling drug and, in the process, bringing discredit on the entire pharmaceutical industry. The PMCPA was created 30 years ago to bolster the industry’s reputation and has become a receptacle for complaints, often by physicians and company employees.

STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week

STAT

JANUARY 8, 2023

SAN FRANCISCO — What should be a triumphant return to the global biotech industry’s biggest annual event, “JPM Week,” after a two-year hiatus is turning as gloomy as Bay Area weather, with industry executives forecasting economic troubles in the year ahead. Morgan Healthcare Conference in San Francisco.

STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation

STAT

MARCH 1, 2024

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drug makers’ constitutional property rights.

Drug Pricing

STAT+: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes

STAT

MAY 17, 2023

It’s a setback for the hospital industry, which has been aggressively fighting that and other efforts to equalize Medicare payments, a set of policy changes known as “site-neutral” rates. Site-neutral policies in Medicare could take more than $150 billion out of the industry over the next decade.

Hospitals

Hospitals Physician Offices Drug Pricing

Opinion: The FDA is the right agency to regulate CBD products, but it needs help

STAT

FEBRUARY 3, 2023

The dietary supplement industry has been begging for federal oversight of products containing cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant that is being incorporated into a bewildering range of oils, tinctures, edibles, and other products. Read the rest…

Compounding

STAT+: Vaccines save lives and generate profits. Why is investment lagging?

STAT

JANUARY 26, 2024

But investment in experimental vaccines for dozens of other diseases remains modest and should be much higher, according to a new biotechnology industry report. Covid vaccines saved nearly 20 million lives worldwide, by one estimate, and generated billions of dollars for several drugmakers. billion, the report said.

Vaccines

Opinion: Why the U.S. needs a public benefit biopharma industry

STAT

OCTOBER 13, 2022

The biopharma industry is failing Americans, economically and medically. Unlike companies in other industries, however, biopharma companies have a special advantage: their products have market exclusivity upon Food and Drug Administration approval, which can be leveraged to maximize pricing for a specified period.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Robert F. Kennedy is pitching centrism on health care, even on abortion

STAT

OCTOBER 10, 2023

In a Monday afternoon Philadelphia rally, the Kennedy family scion harkened back to the Declaration of Independence and “the one other president who did not have a political party” (George Washington), promising to take on D.C. influence and the powerful industry players who sway it, including pharmaceutical companies.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

STAT+: The biggest health care deals of 2023

STAT

DECEMBER 17, 2023

Every year, the health care industry behaves more and more like a balloon: Squeeze one side, and the other expands. Companies that were once just insurers or just pharmacies are tacking on new business lines. The idea is that when profit inevitably gets squeezed in one, it’ll expand in another.

Hospitals

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT

JANUARY 8, 2024

The nonprofit will establish the laboratories at Mayo Clinic, Duke, Stanford, and other major universities and institutions around the country. Its goal is to create a system to certify and register AI models, and publish details about their performance before they are widely adopted.

Mayo Clinic

Mayo Clinic Hospitals

STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations

STAT

MAY 17, 2023

The Federal Trade Commission is widening its probe into pharmacy benefit managers and their impact on drug pricing by looking into a pair of group purchasing organizations that are owned by these industry middlemen, but are not well understood outside the industry. Continue to STAT+ to read the full story…

Drug Pricing

Drug Pricing Documentation

STAT+: Lasers, cardiology, clinical trials: 2023’s top private equity targets

STAT

FEBRUARY 8, 2024

Each of the three niches continue to generate buzz among investors, even as other areas fizzle. Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023.

Hospitals

Weight Loss Industry Market Hit New High in 2023 Due to Weight Loss Drugs and Other Medical Interventions

PharmExec

MARCH 11, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

STAT+: Ultima Genomics launching high-end DNA sequencers that can read genome for $100

STAT

JANUARY 30, 2024

The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. Continue to STAT+ to read the full story…

STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies

STAT

MARCH 13, 2024

In a setback to the pharmaceutical industry, a U.S. As a result, other states can now be expected to pursue similar laws. appeals court has upheld an Arkansas law that allows hospitals participating in a controversial federal discount program to ship medicines to certain pharmacies.

Hospitals

Hospitals Pharmaceutical Companies Pharmaceutical Companies

STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

STAT

OCTOBER 3, 2023

In the latest battle over access to medicines, Colombian authorities have decided to issue a compulsory license for a needed HIV treatment, a step that underscores ongoing friction between the pharmaceutical industry and cash-strapped governments around the world.

STAT+: Medicare is a tricky market for telehealth companies. Why is Talkspace betting on it?

STAT

MARCH 4, 2024

The company claims its 130 million people have access to its services through deals with insurers, employers, or through other arrangements, and it is now knocking on the door of profitability — an impressive feat for any digital health company. Continue to STAT+ to read the full story…

STAT+: While other states, countries have biotech envy, Massachusetts can’t find enough workers

STAT

JUNE 7, 2023

While other states and nations came to the global BIO 2023 convention in Boston this week on the hunt for investors and companies to grow their biotech sectors, Massachusetts has a different problem: It can’t find enough workers to fill positions.

STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds

What can pharma marketing learn from other regulated industries?

Trending Sources

STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum

STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders

STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China

Red Jacket: Ken Getz, a champion of clinical trials

A STAT analysis shows how top drug companies are starting to take action on climate

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

STAT+: UnitedHealth cyberattack cripples pharmacies’ and hospitals’ ability to process insurance claims

FTC sues private equity firm Welsh Carson, U.S. Anesthesia Partners for allegedly creating a monopoly

Cannabis industry scales back its lobbying in Washington

Opinion: STAT+: Continuous manufacturing can help pharma companies save time, money, and more

A biotech tackles drug discovery with transcription factor know-how

STAT+: FTC says pharmacy benefit managers are stonewalling requests for information

Opinion: Where do we go from here on digital therapeutics?

Opinion: Americans are obsessed with health and fitness tracking. It’s time for a data diet

STAT+: U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments

What’s on tap at HLTH, the health care industry jamboree that kicks off this weekend

STAT+: Morgan Health wants you to know it’s still here

STAT+: Hospitals try a new pitch to investors: other ways of making money

STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more

STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more

STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues

STAT+: Net prices for medicines fell considerably in 2023’s last quarter, mostly thanks to Humira biosimilars

Submit your essay to First Opinion

STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing

STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week

STAT+: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation

STAT+: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes

Opinion: The FDA is the right agency to regulate CBD products, but it needs help

STAT+: Vaccines save lives and generate profits. Why is investment lagging?

Opinion: Why the U.S. needs a public benefit biopharma industry

Robert F. Kennedy is pitching centrism on health care, even on abortion

STAT+: The biggest health care deals of 2023

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations

STAT+: Lasers, cardiology, clinical trials: 2023’s top private equity targets

Weight Loss Industry Market Hit New High in 2023 Due to Weight Loss Drugs and Other Medical Interventions

STAT+: Ultima Genomics launching high-end DNA sequencers that can read genome for $100

STAT+: Pharma loses a key battle over a state law concerning 340B pharmacies

STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

STAT+: Medicare is a tricky market for telehealth companies. Why is Talkspace betting on it?

STAT+: While other states, countries have biotech envy, Massachusetts can’t find enough workers

Stay Connected